ABP Abpro Corporation
USHealthcareAs of 2026-03-09 16:00
Why ABP matters now
Abpro Corporation (ABP) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.52 with +0.00% on the session and $1.1M in market capitalization; recent performance reads 1-month +378.90% and YTD -87.63%.
The latest financial table shown here is Q3 2025, with revenue of $0.00, net income of $-1.7M, and EPS of $-0.63. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -1421.3%.
Additional event context on this page matters because analyst consensus is Hold with a median target of $—. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.00
P/S
0.00
EV/EBITDA
0.66
DCF Value
$-16.17
FCF Yield
-1421.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
73.5%
ROA
-139.2%
ROIC
382.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $0.00 | $-1.7M | $-0.63 |
| Q2 2025 | $0.00 | $-3.0M | $-1.56 |
| Q1 2025 | $0.00 | $-3.9M | $-2.40 |
| Q4 2024 | $183.0K | $-5.5M | $-17.70 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Related Stocks
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
-0.00
Abpro Holdings, Inc. is a biotechnology firm dedicated to creating antibody-based treatments for patients suffering from conditions in immuno-oncology, ophthalmology, and autoimmunity. A key element of their strategy is the proprietary DiversImmune platform, which aims to resolve a significant hurdle in the antibody therapeutics sector. Their primary investigational drug candidates include ABP-100, designed to target breast, gastric, and colorectal cancers, and ABP-201, intended for the treatment of vascular diseases affecting the eye. The company has established strategic alliances with Abpro Bio Co. Ltd and NJCTTQ. Originally known as Abpro Corporation, the company officially changed its name to Abpro Holdings, Inc. in November 2024. Incorporated in 2004, Abpro Holdings, Inc. operates from its headquarters in Woburn, Massachusetts.